By Fineline Cube 
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that the National Medical Products Administration (NMPA) has accepted the marketing authorization application for hetrombopag olamine tablets. The new indication covers the treatment of thrombocytopenia in adult patients undergoing predominantly chemotherapy-based anti-tumor therapy.
Drug Mechanism
Hetrombopag olamine is an oral, non-peptide thrombopoietin receptor (TPO-R) agonist. It works by activating the TPO-R-mediated STAT and MAPK signaling pathways to promote platelet production.
Previous Approvals
The drug was previously approved in China for two indications:
- Treatment of adults with chronic primary immune thrombocytopenia who have had an insufficient response to corticosteroids or immunoglobulins.
- Treatment of adults with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.-Fineline Info & Tech